Global Markets Alkem operates in over 50 countries with 32% of revenue from offshore sales. The company maintains 21 manufacturing facilities in India and the US and holds cGMP approvals from USFDA, MHRA, ANVISA, TGA and other regulators, creating a strong platform for international partnerships and accelerated product registrations.

Scale and Capex A broad manufacturing footprint and ongoing expansion including a major plant investment in Ujjain and new Dubai export presence provide capacity for contract manufacturing, co development, and rapid scaling to meet surging demand in existing and new markets.

Innovation Engine With 500 plus scientists across five global R&D centers and recent launches such as ready to use semaglutide syringes, advanced ceramide boosting products, and new multivitamin lines, there are opportunities for licensing, co development, and white label partnerships in high growth therapeutic and consumer health segments.

Growth Momentum Strong top line growth with double digit YoY revenue increases and a solid capital markets history positioning the company for strategic partnerships, acquisitions, or expanded manufacturing and distribution arrangements across geographies.

Anti Infective Leadership Well established leadership in the anti infective space and a portfolio of top Indian brands provide a platform to expand generic manufacturing collaborations, DMF filings, and global distribution deals leveraging brand trust and regulatory know how.